Introduction
============

Refractory angina is characterized by severe and persistent cardiac discomfort ^[@r01],[@r02]^ and is resistant to traditional cardiological treatments, including coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), and maximum drug therapy ^[@r01],[@r02]^. In the United States alone, there are approximately 300,000 to 900,000 cases of refractory angina; in addition, about 25,000 to 75,000 new patients are diagnosed each year ^[@r03]^. Gene therapy, which has the potential to promote myocardial angiogenesis and collateral circulation in ischemic myocardium, may represent a possible treatment modality for these patients ^[@r04]^.

Angiogenesis involves the mobilization of endothelial progenitor cells (EPCs), which are multipotent cells with the capacity to proliferate and differentiate into mature endothelial cells ^[@r05]^. Gene therapy using vascular endothelial growth factor (VEGF) 165 appears to promote the mobilization of EPCs ^[@r06]^, but very little is known about the behavior of such cells in patients with refractory angina who have undergone gene therapy with high doses of VEGF 165.

Most studies using VEGF 165 in patients with ischemic heart disease have been conducted in combination with other interventions such as CABG and PCI ^[@r07]-[@r10]^. However, a class of patients exists who are not eligible for such interventions; therefore, these combined treatments are not an option for them ^[@r01],[@r02]^. In such situations, gene therapy alone may be a possible solution, but till date, only a few studies have been conducted, with most of them using low doses of VEGF (125-250 µg) ^[@r09],[@r11],[@r12]^. Therefore, the behavior of EPCs in patients receiving gene therapy with high doses of VEGF remains unclear.

The present study aimed to assess the behavior of EPCs in patients with ischemic heart disease and refractory angina who received an intramyocardial injection of 2000 µg of VEGF 165 as the sole therapy.

Methods
=======

Study Design
------------

This was a subanalysis of a trial registered as ClinicalTrial.gov NCT 00744315 ^[@r04]^, which aimed to evaluate the safety, feasibility, and initial clinical effects of intramyocardial transthoracic administration of plasmid VEGF 165 on myocardial perfusion in patients with advanced coronary artery disease and refractory angina who did not qualify for percutaneous or surgical revascularization. The rationale and design of this trial have been described previously ^[@r04]^. This was the first clinical trial that used gene therapy for patients with refractory angina in Latin America. The protocol was approved by the local Ethics Committee, and all patients provided written informed consent prior to participation.

Study Participants
------------------

Patients with advanced ischemic heart disease who were contraindicated for CABG or PCI as assessed by a cardiovascular surgeon and interventional cardiologist were eligible for enrollment. Inclusion criteria were as follows: signs and symptoms of angina and/or heart failure despite maximum medical treatment and a myocardial ischemic area of at least 5% as assessed by single-photon emission computed tomography (SPECT). Exclusion criteria were as follows: age \> 65 years, left ventricular ejection fraction \< 25%, and a cancer diagnosed. The subanalysis included only those patients whose EPC levels were assessed during the study.

Intervention
------------

All patients were submitted to surgical intervention under general anesthesia at a center specializing in cardiovascular surgery. The heart was exposed by an incision of approximately 5 cm at the 4th or 5th left intercostal space according to the area to be treated. An extensive pericardiotomy was placed and was followed by pericardial repair. The area to receive the plasmid vector solution injection was identified by preoperative myocardial SPECT. Under direct vision, 10 points of the ischemic myocardium received a total of 2000 µg of gene VEGF 165 plasmid, which was diluted in a total of 5 ml of saline solution, via a 25F butterfly injection needle. Prior to thoracography, a thoracic tube was placed and maintained for 12 h. Postoperative pain was managed using intercostal block and injectable analgesics.

Plasmid Vector
--------------

The plasmid backbone used was developed by one of our team members Sang W. Han at the Federal University of São Paulo and produced commercially by Excellion Technology (Brazil, Petropolis, RJ). The plasmid backbone of PEX-HV5 was composed of cytomegalovirus (CMV) intron 1 and its promoter with splicing signals. The human VEGF165 cDNA was inserted between the CMV promoter and the bovine polyA sequence. This vector also contained a pUC origin and kanamycin resistance sequences for propagation in bacteria.

Outcomes
--------

EPCs were analyzed using flow cytometry before and 3, 9, and 27 days after intervention. Mononuclear cells were separated from the peripheral blood using a Ficoll gradient (Ficoll-Paque, Invitrogen). Immunophenotyping was performed by specific staining with anti-CD34 (BD Biosciences) and anti-KDR (BD Biosciences) conjugated to the fluorophores fluorescein isothiocyanate (FITC) and phycoerythrin (PE), respectively. The CD34+ and KDR+ populations were analyzed in the FACSCalibur cytometer using CellQuest software in collaboration with the Laboratory of Immunogenetics at the Department of Genetics, Federal University of Rio Grande do Sul. The frequency of CD34+/KDR+ cells was analyzed in the lymphocyte gate in the peripheral blood mononuclear fraction and 100,000 events were counted. The results show the number of double-positive cells (n/100.000 cells).

Statistical Methods
-------------------

Continuous variables are expressed as means and standard deviations and categorical variables as absolute and relative frequencies. The Friedman nonparametric test was used to compare the same variable at different times. Analyses were performed using the SPSS 18.0 statistical package.

Results
=======

Patients
--------

Of the 13 patients enrolled in the primary trial, 9 (8 males; mean age, 58.4 ± 5.5 years; mean left ventricular ejection fraction, 59.3% ± 8.8%) underwent assessment of EPCs and were included in the subanalysis. the patients workflow of the study is demonstrated in [Figure 1](#f01){ref-type="fig"}.
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Eight patients were hypertensive and 4 had diabetes. A majority of patients suffered from class III angina. All patients had previously undergone PCI, and 7 of them had also undergone CABG. These findings indicated the severity of ischemic disease in these patients ([Table 1](#t01){ref-type="table"}).

###### 

Demographic, clinical, and angiographic characteristics

  **Characteristics**                     **N (%)**                            
  --------------------------------------- ------------------------------------ ---------
  Male                                    8 (89)                               
  Age\*                                   58.4 ± 5.5                           
  Left Ventricular Ejection Fraction\*    59.3 ± 8.8                           
  Hypertension                            8 (89)                               
  Diabetes                                4 (44)                               
  Angina Class (CCS)                                                           
                                          III                                  7 (78)
                                          IV                                   2 (22)
  Previous Miocardial Revascularization                                        
                                          Percutaneous Coronary Intervention   9 (100)
                                          Coronary Artery Bypass Grafting      7 (78)

\*average and standard deviation. CCS: Canadian Cardiology Society.

Outcomes
========

There were no deaths or recurrences. The therapy was demonstrated to be safe and feasible in this series of patients. Initial results showed a decrease in the severity of angina and intensity of myocardial ischemia, as previously described by our group ^[@r04]^.

Analyses of EPCs demonstrated an increase in the number of cells on the 3th day after intervention compared to baseline (baseline, 42.7 ± 19.2; day 3, 66.6 ± 34.3; p = 0.03). However, the number of EPCs decreased to become comparable to baseline on days 9 and 27 (baseline, 42.7 ± 19.2; day 9, 34.9 ± 15.0; baseline, 42.7 ± 19.2; day 27, 36.1 ± 12.9; p = NS for both; [Figure 2](#f02){ref-type="fig"}).
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Discussion
==========

This study was the first, as per our knowledge, that assessed the mobilization of EPCs in patients with ischemic heart disease and refractory angina who underwent gene therapy with 2000 µg of VEGF 165. Our results showed a transient mobilization of EPCs, with peak on the 3th day after gene therapy.

A previous study evaluating mobilization of EPCs after gene therapy^[@r06]^ administered 250 µg of intramyocardial VEGF 165 to 13 patients with myocardial ischemia and reported a peak of EPCs during week 1 and week 4 after the intervention. However, besides using a substantially smaller dose of VEGF, their results of flow cytometry were obtained based on histograms of 10,000 to 20,000 cells per sample, while we used the number of double-positive n/100.000 cells. Thus, making difficult the comparison between the trials.

EPCs have the ability to home in vascular injury sites and contribute to neoangiogenesis ^[@r13]^. Mobilization of EPCs from the bone marrow in response to different signals has also been well described ^[@r05]^. Previous studies have demonstrated the ability of VEGF to promote EPC mobilization *in vivo* and EPC differentiation *in vitro* ^[@r14],[@r15]^. In addition, circulating EPCs have been shown to contribute to the neovascularization process ^[@r16]^. The transient mobilization of EPCs after gene therapy as observed in our study is in agreement with the findings of previous experimental and clinical studies ^[@r06]^. VEGF expression after gene therapy seems to be transient ^[@r06]^. Previous studies have shown a positive correlation between circulating EPCs and plasma VEGF levels ^[@r06],[@r14]^, which may help explain the transient mobilization of EPCs. In addition, we suggest that permanent cell expression of VEGF and constant mobilization of EPCs after gene therapy are undesirable since such activity may increase the risk of tumor formation because of the possibility of uncontrolled cell multiplication. Therefore, it is desirable to achieve transient expression of VEGF and mobilization of EPCs, which is sufficient for the process of angiogenesis, formation of collateral circulation in ischemic myocardium, and with a subsequent improvement in myocardial perfusion. The results for mobilization of EPCs in this study were promising in this regard.

The small sample of patients may be thought to limit the power of the study; however, this sample size is derived from a phase I/II clinical trial ^[@r04]^ to test the safety and feasibility of 2000 *µ*g of VEGF 165 as the sole therapy for ischemic heart disease with refractory angina. Such studies aim to test the safety and feasibility of the procedure and provide initial clinical results, and they usually include small sample of patients for safety reasons. This study contributes to the understanding of EPC behavior and the myocardial angiogenic process after gene therapy with high doses of VEGF 165. Information obtained from this study can thus be used as a rationale for future phase II or III clinical trials.

Conclusion
==========

We identified a transient mobilization of EPCs, which peaked on the 3th day and returned to baseline levels on the 9^th^ and 27^th^ days after gene therapy with 2000 µg of VEGF 165 in patients with refractory angina.
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